Modified-versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: A randomized, phase III, non-inferiority study

Rheumatology (United Kingdom)

Volumn 58, Issue 1, 2019, Pages 70-79

  Tanaka, Yoshiya ^a   Sugiyama, Naonobu ^b   Toyoizumi, Shigeyuki ^b   Lukic, Tatjana ^b   Lamba, Manisha ^b   Zhang, Richard ^b   Chen, Connie ^b   Stock, Thomas ^b   Valdez, Hernan ^b   Mojcik, Christopher ^b   Fan, Haiyun ^b   Deng, Chenhui ^b   Yuasa, Hirotoshi ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b PFIZER INC   (United States)

Author keywords

Japan; Non inferiority; Once daily; RA; Tofacitinib; Twice daily

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GLUCOCORTICOID; METHOTREXATE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DIARRHEA; DOUBLE BLIND PROCEDURE; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS QUESTIONNAIRE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HEPATOBILIARY DISEASE; HUMAN; JAPANESE (PEOPLE); LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; STOMATITIS; THORAX DISEASE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; ENZYMOLOGY; JAPAN; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JANUS KINASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 85058881485     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key250     Document Type: Article

References (26)

1. Fleischmann R, Cutolo M, Genovese MC et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29.
2. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
3. Kremer JM, Cohen S, Wilkinson BE et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81.
4. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 2011;63:1150-8.
5. Tanaka Y, Takeuchi T, Yamanaka H et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015;25:514-21.
6. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
7. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
8. Kremer J, Li Z-G, Hall S et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61.
9. Lee EB, Fleischmann R, Hall S et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
10. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
11. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
12. Wollenhaupt J, Silverfield J, Lee EB et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837-52.
13. Wollenhaupt J, Silverfield J, Lee EB et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. Arthritis Rheumatol 2017;69:683-4.
14. Yamanaka H, Tanaka Y, Takeuchi T et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 2016;18:34.
15. Waterman KC, MacDonald BC, Roy MC. Extrudable core system: development of a single-layer osmotic controlledrelease tablet. J Control Release 2009;134:201-6.
16. Coleman CI, Limone B, Sobieraj DM et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527-39.
17. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33.
18. Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35.
19. Lamba M, Wang R, Fletcher T et al. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol 2016;56:1362-71.
20. Lamba M, Hutmacher MM, Furst DE et al. Model-informed development and registration of a once-daily regimen of extended-release tofacitinib. Clin Pharmacol Ther 2017;101:745-53.
21. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
22. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93-9.
24. Food and Drug Administration. Guidance for Industry: Non-inferiority Clinical Trials to Establish Effectiveness. 2016: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm202140. pdf (10 July 2017, date last accessed).
25. Fleischmann R, Kremer J, Tanaka Y et al. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. Int J Rheum Dis 2016;19:1216-25.
26. Cohen SB, Tanaka Y, Mariette X et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253-62.